Catalent (NYSE:CTLT) Hits New 12-Month Low at $85.10

Catalent, Inc. (NYSE:CTLTGet Rating)’s share price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $85.10 and last traded at $86.63, with a volume of 8801 shares trading hands. The stock had previously closed at $87.15.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on CTLT shares. StockNews.com lowered shares of Catalent from a “hold” rating to a “sell” rating in a research report on Saturday, September 17th. Barclays lowered their price objective on shares of Catalent from $130.00 to $115.00 and set an “overweight” rating for the company in a report on Tuesday, August 30th. Royal Bank of Canada lowered their price objective on shares of Catalent from $155.00 to $125.00 and set an “outperform” rating for the company in a report on Tuesday, August 30th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Catalent from $110.00 to $105.00 and set a “hold” rating for the company in a report on Tuesday, August 30th. Finally, Stephens lowered their price target on shares of Catalent to $145.00 in a report on Tuesday, September 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $122.13.

Catalent Stock Down 4.9 %

The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.07 and a current ratio of 2.72. The company’s fifty day moving average is $100.65 and its 200-day moving average is $102.12. The company has a market capitalization of $14.22 billion, a PE ratio of 27.94, a price-to-earnings-growth ratio of 1.71 and a beta of 1.36.

Catalent (NYSE:CTLTGet Rating) last issued its quarterly earnings results on Monday, August 29th. The company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.15 by $0.04. Catalent had a return on equity of 14.49% and a net margin of 10.56%. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same period last year, the company earned $1.08 earnings per share. Catalent’s revenue was up 10.5% on a year-over-year basis. As a group, analysts predict that Catalent, Inc. will post 3.66 EPS for the current fiscal year.

Insider Activity

In other news, CEO Alessandro Maselli sold 816 shares of the firm’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total transaction of $87,230.40. Following the transaction, the chief executive officer now owns 25,083 shares in the company, valued at $2,681,372.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Catalent news, CEO Alessandro Maselli sold 816 shares of Catalent stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total value of $87,230.40. Following the transaction, the chief executive officer now owns 25,083 shares in the company, valued at $2,681,372.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Kay A. Schmidt sold 323 shares of Catalent stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total value of $34,528.70. Following the completion of the transaction, the senior vice president now owns 13,455 shares in the company, valued at approximately $1,438,339.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,018 shares of company stock worth $1,873,343. Company insiders own 0.53% of the company’s stock.

Institutional Investors Weigh In On Catalent

A number of large investors have recently modified their holdings of CTLT. Prospera Financial Services Inc purchased a new stake in shares of Catalent during the first quarter worth about $33,000. Parkside Financial Bank & Trust grew its stake in shares of Catalent by 127.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 282 shares of the company’s stock worth $36,000 after acquiring an additional 158 shares during the last quarter. CX Institutional purchased a new stake in shares of Catalent during the second quarter worth about $37,000. Clear Street Markets LLC grew its stake in shares of Catalent by 408.1% during the second quarter. Clear Street Markets LLC now owns 376 shares of the company’s stock worth $40,000 after acquiring an additional 302 shares during the last quarter. Finally, Ellevest Inc. grew its stake in shares of Catalent by 39.5% during the first quarter. Ellevest Inc. now owns 406 shares of the company’s stock worth $45,000 after acquiring an additional 115 shares during the last quarter. Hedge funds and other institutional investors own 90.54% of the company’s stock.

About Catalent

(Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Further Reading

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.